Hyaluronic acid filler treatment for mid-face volume lasted up to 2 years

Hyaluronic acid filler treatment effectively corrected loss of volume in the mid-face for up to 2 years, according to research presented at The Aesthetic Meeting in San Francisco.

“Most patients undergoing mid-face volume injections of hyaluronic acid understand that the results they see from treatment will be temporary and sustaining improvement will require a return visit. The question is always ‘How soon?’” researcher Jeffrey M. Kenkel, MD, FACS, professor and vice chair of plastic surgery at the University of Texas Southwestern in Dallas, said in a press release from the American Society for Aesthetic Plastic Surgery annual meeting. “The results from this study will now help physicians better prepare their patients and more accurately plan their next treatment visit.”

Jeffrey M. Kenkel

Fifteen investigators in the US treated 235 patients with hyaluronic acid filler for volume loss in the mid-face. A validated 6-point Mid-Face Volume Deficit Scale was used by the treating physician and two masked physicians to measure treatment results.

“The evaluations showed that hyaluronic acid treatment for age-related mid-face volume deficit was effective in the range of 2 mL injection volume per sub-region,” Kenkel and fellow researchers reported.

Result duration ranged from 15 months to 24 months, with the anteromedial cheek region experiencing the longest duration. Duration of effect was related to the volume of hyaluronic acid used and the facial region being treated, according to the release.

“We now have a more concrete understanding of how to administer these kinds of treatments over time, and a more precise understanding of how to treat each mid-facial region,” Kenkel concluded.

For more information:

JM Kenkel. Duration of Effect by Injection Volume and Facial Sub-Region for a Volumizing Hyaluronic Acid Filler in Treating Mid-Face Volume Deficit. Presented at: The Aesthetic Meeting 2014; April 24-29, San Francisco.

Disclosure: Kenkel reported financial ties with Ulthera, Allergan, Kythera Biopharmaceuticals, UltraShape and Solta Medical.